AbbVie (AbbVie) Risk Assessment

View and export this data going back to 2012. Start your Free Trial

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of AbbVie is: Low Risk: Strong fundamentals, worth long-term holding.

Competitive Comparison

For the Drug Manufacturers - General subindustry, AbbVie's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AbbVie Risk Assessment Distribution

For the Drug Manufacturers industry and Healthcare sector, AbbVie's Risk Assessment distribution charts can be found below:

* The bar in red indicates where AbbVie's Risk Assessment falls into.

AbbVie (NYSE:ABBV) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

AbbVie Risk Assessment Related Terms

Thank you for viewing the detailed overview of AbbVie's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

AbbVie (AbbVie) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AbbVie Inc (NYSE:ABBV) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

ABBV:Mexico 1ABBV:Italy 4ABd:UK 0QCV:UK 4AB0:Germany 4AB:Germany 4AB:Germany 4AB:Germany ABBV:Canada ABBV34:Brazil ABBV:Austria

Address

1 North Waukegan Road, North Chicago, IL, USA, 60064-6400

Website

http://www.abbvieinvestor.com

AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Executives

Nicholas Donoghoe	officer: SVP, Enterprise Innovation	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Susan E Quaggin	director	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Jennifer L. Davis	director	1 PROCTER & GAMBLE PLAZA, CINCINNATI OH 45202
Richard A Gonzalez	officer: Chairman of the Board and CEO	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Elaine K. Sorg	officer: Sr. V.P., U.S. Commercial Ops.	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Perry C Siatis	officer: EVP, GC and Secretary	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Jeffrey Ryan Stewart	officer: SVP, US Commercial Operations	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Kevin K Buckbee	officer: SVP, Controller	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Scott T Reents	officer: SVP, Chief Financial Officer	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Azita Saleki-gerhardt	officer: SVP, Operations	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Carrie C Strom	officer: SVP & Pres Global Allerg Aesth	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Roxanne S Austin	director	200 N SEPULVEDA BLVD, PO BOX 956 MS ES/001/A102, EL SEGUNDO CA 90245
Timothy J. Richmond	officer: EVP, Chief HR Officer	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Michael Severino	officer: EVP, R&D and CSO	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Henry O Gosebruch	officer: Chief Strategy Officer	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064-6092